Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)
Dose-reduction of osimertinib was relatively uncommon and associated with shorter PFS (primarilyCNS progression), but similar TTD and OS in 1 L patients withEGFR-mutated mNSCLC.
Authors
- Adam Barsouk (ORCID: https://orcid.org/0000-0003-2333-7530)
- Lucy S. Wang (ORCID: https://orcid.org/0000-0002-7313-3264)
- Lauren Reed-Guy
- Lynn Rushkin
- Alec Heidlauf
- Anna Anran Huang
- Roger B. Cohen
- Lova Sun
- Keshav Goel
- Aditi Singh
- Connie Yu
- Melina E. Marmarelis
- David Yang
- Corey Langer
- Charu Aggarwal
- Omar Elghawy
- Martin Kurian
Institutions
- University of Pennsylvania (US)
Publication Details
- Journal
- Lung Cancer
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1016/j.lungcan.2026.108936
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 36.44